Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent

Trial Details

NCT ID

NCT04924075

Phase

PHASE2

Sponsor

Merck Sharp & Dohme LLC

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Belzutifan

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368
Chicago, Illinois, United States|41.85003,-87.65005
Iowa City, Iowa, United States|41.66113,-91.53017
Baltimore, Maryland, United States|39.29038,-76.61219
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-L…
Cohort BI: VHL Disease-associated tumors:
Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →